TGFbeta/BMP inhibits the bone marrow transformation capability of Hoxa9 by repressing its DNA-binding ability

The EMBO Journal
Ning WangXu Cao

Abstract

Homeobox (Hox) gene mutations and their altered expressions are frequently linked to human leukemia. Here, we report that transforming growth factor beta (TGFbeta)/bone morphogenetic protein (BMP) inhibits the bone marrow transformation capability of Hoxa9 and Nup98-Hoxa9, the chimeric fusion form of Hoxa9 identified in human acute myeloid leukemia (AML), through Smad4, the common Smad (Co-Smad) in the TGFbeta/BMP signaling pathway. Smad4 interacts directly with the homeodomain of Hoxa9 and blocks the ability of Nup98-Hoxa9 to bind DNA, thereby suppressing its ability to regulate downstream gene transcription. Mapping data revealed that the amino-terminus of Smad4 mediates this interaction and overexpression of the Hoxa9 interaction domain of Smad4 was sufficient to inhibit the enhanced serial replating ability of primary bone marrow cells induced by Nup98-Hoxa9. These studies establish a novel mechanism by which TGFbeta/BMP regulates hematopoiesis and suggest that modification of Hox DNA-binding activity may serve as a novel therapeutic intervention for those leukemias that involve deregulation of Hox.

References

Dec 6, 1994·Proceedings of the National Academy of Sciences of the United States of America·G SauvageauR K Humphries
Oct 1, 1995·Molecular and Cellular Biology·J J MoskowA M Buchberg
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·M T AndersonL A Herzenberg
Apr 1, 1997·Trends in Genetics : TIG·M SharkeyM P Scott
May 27, 1997·Proceedings of the National Academy of Sciences of the United States of America·J F DeCoteauM E Kadin
Jan 9, 1999·The Journal of Biological Chemistry·C V PatelP E DiCorleto
Mar 19, 1999·Molecular and Cellular Biology·W F ShenC Largman
Apr 6, 1999·The Journal of Experimental Medicine·M BhatiaJ E Dick
Apr 13, 1999·Cell·D WottonJ Massagué
Jan 8, 2000·The Journal of Biological Chemistry·X YangX Cao
Mar 18, 2000·The Journal of Biological Chemistry·S BaiX Cao
Oct 24, 2000·The Journal of Biological Chemistry·X ShiX Cao
Dec 6, 2000·European Journal of Biochemistry·S ItohP Ten Dijke
Mar 10, 2001·Experimental Cell Research·A Hata
Jun 1, 2002·Science·Liliana Attisano, Jeffrey L Wrana
Jun 18, 2002·Blood Cells, Molecules & Diseases·Ota FuchsTomas Stopka
Nov 22, 2002·Leukemia Research·Albertus T J WierengaEdo Vellenga
Oct 17, 2003·The Journal of Biological Chemistry·Ghada GhannamNabeel R Yaseen
Nov 8, 2003·Blood·Sheri Tinnell DorsamH Jeffrey Lawrence
Dec 13, 2003·Proceedings of the National Academy of Sciences of the United States of America·Shigeru ChibaHisamaru Hirai
Feb 28, 2004·The Journal of Biological Chemistry·Mei WanXu Cao
Jun 21, 2005·Experimental Hematology·Malcolm A S Moore

❮ Previous
Next ❯

Citations

Aug 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Serge PlazaWalter J Gehring
May 23, 2012·Proceedings of the National Academy of Sciences of the United States of America·Bo ZhouGuang Zhu
Feb 8, 2011·Journal of Biomolecular Structure & Dynamics·Sujata Roy, Ashoke Ranjan Thakur
Nov 19, 2010·Stem Cells and Development·Helen WheadonAlexander Thompson
Apr 25, 2007·Molecular and Cellular Biology·Smarajit BandyopadhyayPaul E DiCorleto
Oct 5, 2007·Blood·Ulrika BlankStefan Karlsson
May 17, 2013·Cell Communication and Signaling : CCS·William A SandsHelen Wheadon
Apr 3, 2015·Blood·Ulrika Blank, Stefan Karlsson
Oct 12, 2013·Developmental Dynamics : an Official Publication of the American Association of Anatomists·René Rezsohazy
Jun 20, 2019·Cancers·Mélanie LambertMarie-Hélène David-Cordonnier
Jan 4, 2007·The Journal of Biological Chemistry·Wendy M KnospH Scott Stadler

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.